Brookstone Capital Management Anavex Life Sciences Corp. Transaction History

Brookstone Capital Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 20, 2023	BUY	$6.55 - $9.37 $2,227 - $3,185	340 Added 2.29%	15,185 $99,000
Q4 2022 Jan 09, 2023	BUY	$7.65 - $14.43 $1,109 - $2,092	145 Added 0.99%	14,845 $0
Q3 2022 Oct 13, 2022	SELL	$8.9 - $12.86 $1,966 - $2,842	-221 Reduced 1.48%	14,700 $155,000
Q2 2022 Jul 11, 2022	BUY	$7.31 - $12.84 $672 - $1,181	92 Added 0.62%	14,921 $191,000
Q1 2022 Apr 12, 2022	BUY	$9.74 - $17.69 $8,697 - $15,797	893 Added 6.41%	14,829 $168,000
Q2 2021 Jul 14, 2021	BUY	$10.16 - $28.86 $141,589 - $402,192	13,936 New	13,936 $354,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $860M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

Stay updated on Brookstone Capital Management with notifications on news.